| 168.79 -0.27 (-0.16%) | 05-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 200.01  |
1-year : | 206.49 |
| Resists | First : | 171.24 |
Second : | 176.78 |
| Pivot price | 169.43 |
|||
| Supports | First : | 162.27 | Second : | 135.01 |
| MAs | MA(5) : | 166.79 |
MA(20) : | 168.98 |
| MA(100) : | 170.72 |
MA(250) : | 155.37 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 52.6 |
D(3) : | 38.7 |
| RSI | RSI(14): 48.8 |
|||
| 52-week | High : | 179.5 | Low : | 120.04 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IBB ] has closed above bottom band by 44.1%. Bollinger Bands are 2.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 171.03 - 171.9 | 171.9 - 172.57 |
| Low: | 166.61 - 167.53 | 167.53 - 168.24 |
| Close: | 167.34 - 168.88 | 168.88 - 170.06 |
The iShares Biotechnology ETF seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector.
Thu, 21 May 2026
6 Best Healthcare Funds and ETFs to Buy Now | Investing - U.S. News Money
Tue, 28 Apr 2026
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now? - Yahoo Finance
Tue, 21 Apr 2026
Should You Invest in the iShares Biotechnology ETF (IBB)? - Yahoo Finance
Tue, 07 Apr 2026
XBI vs. IBB: The Biotech ETF Showdown That Analysts Say Has a Clear Winner in 2026 - 24/7 Wall St.
Sat, 21 Mar 2026
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing - The Motley Fool
Wed, 25 Feb 2026
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|